{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"18.1","value":"5.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"20.6","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"CR was defined as the disappearance of all target lesions, with any pathological lymph nodes (whether target or non-target) showing a reduction in the short axis to \\<10 mm.Tumor marker results were required to have normalized.","dispersionType":"80% Confidence Interval","groups":[{"description":"Participants received the following treatments in a 28-day cycle, continuing until disease progression or a criterion for discontinuation was met.\n\n* Ramucirumab administered intravenously at a dose of 12 mg/kg as a one-hour infusion on days 1 and 15.\n* Cyclophosphamide administered orally at 25 mg/m² daily from days 1 to 28.\n* Vinorelbine administered intravenously at 25 mg/m² on days 1, 8, and 15.","id":"OG000","title":"Ramucirumab + Cyclophosphamide + Vinorelbine"},{"description":"Participants received the following treatments in a 28-day cycle, continuing until disease progression or a criterion for discontinuation was met.\n\n* Cyclophosphamide administered orally at 25 mg/m² daily from days 1 to 28.\n* Vinorelbine administered intravenously at 25 mg/m² on days 1, 8, and 15.","id":"OG001","title":"Cyclophosphamide + Vinorelbine"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Randomization until measured progressive disease (Up To 23 Months)","title":"Complete Response (CR) : Percentage of Participants Who Achieved a CR","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}